# Merck to acquire Acceleron Pharma for $11.5 billion

Merck (known as MSD outside US and Canada) announced a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, totaling approximately $11.5 billion equity value. Acceleron focuses on TGF-beta superfamily therapies, including sotatercept for pulmonary arterial hypertension and REBLOZYL for anemia.

- Type: Acquisition
- Announced: 2021-09-30
- Where: United States
- Value: $11.5B
- Status: announced
- Products: sotatercept, REBLOZYL (luspatercept-aamt)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Merck](https://endata.com/companies/1841.md) (acquirer)
- [Acceleron Pharma Inc.](https://endata.com/companies/58053.md) (target)

## Sources

- [merck.com](https://www.merck.com/news/merck-to-acquire-acceleron-pharma-inc/), 2021-09-30: "Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.